Insulet Corporation $PODD Shares Sold by William Blair Investment Management LLC

William Blair Investment Management LLC decreased its stake in shares of Insulet Corporation (NASDAQ:PODD) by 50.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 145,811 shares of the medical instruments supplier’s stock after selling 147,692 shares during the period. William Blair Investment Management LLC owned approximately 0.21% of Insulet worth $41,445,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of PODD. Larson Financial Group LLC increased its stake in Insulet by 114.6% during the 4th quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock valued at $25,000 after buying an additional 47 shares during the period. Elyxium Wealth LLC acquired a new position in Insulet during the 4th quarter valued at about $28,000. Whittier Trust Co. of Nevada Inc. increased its stake in Insulet by 48.9% during the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 131 shares of the medical instruments supplier’s stock valued at $40,000 after buying an additional 43 shares during the period. Measured Wealth Private Client Group LLC acquired a new position in Insulet during the 3rd quarter valued at about $49,000. Finally, Osterweis Capital Management Inc. acquired a new position in Insulet during the 2nd quarter valued at about $51,000.

Insulet Stock Performance

Shares of PODD opened at $154.87 on Monday. Insulet Corporation has a one year low of $145.59 and a one year high of $354.88. The company has a 50-day moving average of $191.53 and a two-hundred day moving average of $250.80. The stock has a market cap of $10.73 billion, a price-to-earnings ratio of 36.02, a PEG ratio of 1.22 and a beta of 1.20. The company has a debt-to-equity ratio of 0.71, a current ratio of 2.49 and a quick ratio of 1.81.

Insulet (NASDAQ:PODD) last announced its earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 EPS for the quarter, topping the consensus estimate of $1.19 by $0.23. Insulet had a net margin of 10.44% and a return on equity of 26.87%. The company had revenue of $761.70 million during the quarter, compared to analysts’ expectations of $729.89 million. During the same period last year, the company posted $1.02 earnings per share. The business’s revenue for the quarter was up 33.9% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.210- EPS. On average, equities research analysts expect that Insulet Corporation will post 6.43 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have commented on PODD. Wall Street Zen raised shares of Insulet from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Raymond James Financial lowered their target price on shares of Insulet from $355.00 to $263.00 in a research note on Thursday, May 7th. Robert W. Baird lowered their price objective on shares of Insulet from $360.00 to $248.00 in a research note on Thursday, May 7th. Oppenheimer lowered their price objective on shares of Insulet from $300.00 to $210.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. Finally, Benchmark initiated coverage on shares of Insulet in a research note on Tuesday, May 12th. They issued a “buy” rating on the stock. Twenty-one research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $254.96.

Insider Activity at Insulet

In other news, Director Michael R. Minogue bought 2,030 shares of the firm’s stock in a transaction on Wednesday, February 25th. The stock was bought at an average cost of $246.23 per share, for a total transaction of $499,846.90. Following the completion of the acquisition, the director directly owned 17,483 shares in the company, valued at $4,304,839.09. This represents a 13.14% increase in their position. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. 0.36% of the stock is currently owned by insiders.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.